SERPING1 variant does not bind kallikrein

Stable Identifier
R-HSA-9651467
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Prekallikrein circulates as a 1:1 molar complex with high molecular weight kininogen (HK). Factor XIIa directly converts prekallikrein to kallikrein, and cleavage of HK by kallikrein generates a pro-inflammatory peptide bradykinin. Bradykinin formed in the contact system acts through the G-protein–coupled bradykinin B2 receptor on the surface of endothelial cells and causes increased vascular permeability and vasodilation resulting in edema formation (Zuraw BL & Christiansen SC 2016). Under physiological conditions kallikrein binds to plasma protease C1-esterase inhibitor (C1-INH or SERPING1) forming a stable and enzymatically inactive complex. SERPING1 blocks the ability of kallikrein to cleave HK and to activate factor XII (Schreiber AD et al. 1973). SERPING1 (C1-INH) also binds and inhibits factor XIIa (Bock et al. 1986). Defective SERPING1 causes dysregulation of the plasma kallikrein-kinin-system with overproduction of bradykinin due to uninhibited effects of activated factor XIIa and plasma kallikrein. SERPING1 deficiency is linked to the pathogenesis of hereditary angioedema (HAE), an autosomal dominant disorder that manifests as recurrent episodes of swelling involving the face, tongue, extremities, gastrointestinal tract, genitalia, and upper airways (Loules G et al. 2018; De Maat S et al. 2018). HAE has been divided into 3 types, 2 of which are attributable to mutant SERPING1 gene. In type I (± 85% of HAE patients with SERPING1 deficiency), mutations are located on any exon in the SERPING1 gene leading to low antigenic and functional levels of SERPING1 due to defective expression of one allele. The type I HAE-linked variants of SERPING1 are thought to negatively affect synthesis, intracellular transport or secretion of the normal SERPING1 (Kramer J et al. 1993; Verpy E et al. 1993; Ernst SC et al. 1996; Haslund D et al. 2019). In a subset of patients with type I HAE, defective SERPING1 variants interacted with wildtype (wt) SERPING1 in a dominant-negative manner and formed intracellular SERPING1 aggregates leading to a reduction in the plasma levels of wt SERPING1 (Haslund D et al. 2019). Importantly, in patient-derived fibroblasts, the administration of wt SERPING1 gene was able to restore the levels of secreted SERPING1 (C1-INH) protein, suggesting that dominant-negative disease mechanisms can be overcome by gene supplementation (Haslund D et al. 2019). Further, administration of plasma-derived SERPING1 increased plasma levels of physiologically relevant functional SERPING1 in patients with HAE (Martinez-Saguer I et al. 2014; Riedl MA et al. 2016; Zuraw BL et al. 2015). In type II HAE (±15% of HAE patients), characterized by normal or elevated levels of dysfunctional SERPING1 (C1-INH) protein, mutations are mostly located in exon 8 of the SERPING1 gene (Verpy E et al. 1995). Exon 8 encodes the reactive center loop (RCL) and the hinge region of SERPING1 which have an important role in protein function (Verpy E et al. 1995). This classification of HAE types has however been challenged by observations of intermediary HAE types, that can arise, when small amounts of dysfunctional SERPING1 is present in the blood stream (Eldering E et al. 1995; Verpy E et al. 1995; Madsen DE et al. 2014).

SERPING1 belongs to the serine protease inhibitor (serpin) super family of structurally similar but functionally diverse proteins that use a conformational change to inhibit target enzymes (Silverman GA et al. 2001; Gettins PG 2002; Law RH et al. 2006). Serpins are globular proteins with a conserved structure of 7- 9 α-helices and 3 β-pleated sheets and a protruding reactive center loop (RCL) (Silverman GA et al. 2001; Gettins PG 2002; Law RH et al. 2006; Sanrattana W et al. 2019). In native serpins, the RCL, located outside the tertiary core of the serpin, forms a flexible stretch of approximately 20 amino acids, which provides structural flexibility in a solvent-exposed environment. They act on their target proteases by means of a suicide-substrate mechanism involving the cleavage of the RCL and its insertion into β-sheet A (Gettins PG 2002; Pan S et al. 2011; Khan MS et al. 2011). As a result, conformational changes take place in the serpins that ultimately trap and inactivate the targeted protease (Gettins PG 2002; Pan S et al. 2011; Khan MS et al. 2011; Sanrattana W et al. 2019). Serpins are conformationally labile and many of the disease-linked mutations of serpins result in misfolding or in pathogenic, inactive polymers (Law RH et al. 2006).

The Reactome event describes failed interaction between SERPING1 variants and kallikrein as the result of point mutations in or near RCL of SERPING1, for example at residues Arg466 or Ala458. The set of SERPING1 variants also includes a SERPING1 variant with deletion of Lys273 which results in acquisition of an N-glycosylation site leading to dysfunctional protein. The mutations annotated in this event were identified in patients with type II HAE.

Literature References
PubMed ID Title Journal Year
2296585 Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene

Levy, NJ, Ramesh, N, Cicardi, M, Harrison, RA, Davis, AE

Proc. Natl. Acad. Sci. U.S.A. 1990
2563376 CpG mutations in the reactive site of human C1 inhibitor

Skriver, K, Radziejewska, E, Silbermann, JA, Donaldson, VH, Bock, SC

J. Biol. Chem. 1989
24552232 High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency

Suffritti, C, Zanichelli, A, Maggioni, L, Bonanni, E, Cugno, M, Cicardi, M

Clin. Exp. Allergy 2014
12773530 The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant

Bos, IG, Lubbers, YT, Roem, D, Abrahams, JP, Hack, CE, Eldering, E

J. Biol. Chem. 2003
8798678 Characterization of C1 inhibitor-Ta. A dysfunctional C1INH with deletion of lysine 251

Zahedi, R, Aulak, KS, Eldering, E, Davis, AE

J. Biol. Chem. 1996
7814636 Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function

Verpy, E, Couture-Tosi, E, Eldering, E, López-Trascasa, M, Späth, P, Meo, T, Tosi, M

J. Clin. Invest. 1995
2026621 Substrate properties of C1 inhibitor Ma (alanine 434----glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status

Skriver, K, Wikoff, WR, Patston, PA, Tausk, F, Schapira, M, Kaplan, AP, Bock, SC

J. Biol. Chem. 1991
2365061 Identification of a new P1 residue mutation (444Arg----Ser) in a dysfunctional C1 inhibitor protein contained in a type II hereditary angioedema plasma

Aulak, KS, Cicardi, M, Harrison, RA

FEBS Lett. 1990
8529136 A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema

Ocejo-Vinyals, JG, Leyva-Cobián, F, Fernández-Luna, JL

Mol. Med. 1995
1451784 A dysfunctional C1 inhibitor protein with a new reactive center mutation (Arg-444-->Leu)

Frangi, D, Aulak, KS, Cicardi, M, Harrison, RA, Davis, AE

FEBS Lett. 1992
Participants
Participant Of
Normal reaction
Disease
Name Identifier Synonyms
C1 inhibitor deficiency 0060002 Quincke edema
Authored
Reviewed
Created
Cite Us!